Drug firms told to strengthen monitoring of medicine side effects

Why this matters: an international story with cross-border implications worth tracking.

India's drug regulator has mandated pharmaceutical companies to establish robust systems for tracking and reporting adverse drug reactions. This directive, stemming from Schedule M of the Drugs and Cosmetics Rules, reinforces the critical need for post-marketing surveillance to ensure patient safety